Related Experiment Video

Updated: Aug 19, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

[Lipoprotein (A) in patients with coronary atherosclerosis]

I E Olofinskaia, E I Volkova, A V Susekov

    Kardiologiia
    |October 1, 1991
    PubMed

    Insights

    Elevated serum lipoprotein (a) levels are linked to coronary heart disease (CHD). This study found higher lipoprotein (a) in CHD patients, especially those with severe three-vessel disease, indicating its association with atherosclerosis.

    Area of Science:

    • Cardiovascular Medicine
    • Clinical Biochemistry
    • Atherosclerosis Research

    Context:

    • Coronary heart disease (CHD) is a significant global health concern.
    • Lipoprotein (a) [LP(a)] is an emerging risk factor for cardiovascular disease.
    • Understanding the role of LP(a) in CHD pathogenesis is crucial for risk stratification.

    Purpose:

    • To investigate the association between serum lipoprotein (a) levels and angiographically documented coronary heart disease.
    • To compare LP(a) levels in patients with varying degrees of coronary artery stenosis and healthy controls.

    Summary:

    • Serum LP(a) levels were measured in 117 CHD patients and control groups.
    • Significantly higher LP(a) levels were observed in CHD patients compared to controls.
    • A notable increase in LP(a) was found in patients with three-vessel disease versus single-vessel disease and controls, independent of traditional lipid markers, age, and sex.

    Impact:

    • These findings support the hypothesis that LP(a) plays a role in the development of coronary atherosclerosis.
    • Elevated LP(a) may serve as an independent risk marker for severe coronary artery disease.
    • Further research into LP(a) could lead to improved diagnostic and therapeutic strategies for CHD.

    More Related Videos

    Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles09:15

    Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

    Published on: November 10, 2017

    Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation06:47

    Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

    Published on: January 28, 2021

    Related Concept Videos

    Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

    Lipid-Lowering Drugs: Statins and Miscellaneous Agents

    Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
    Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

    Blood Studies for Cardiovascular System III: Serum Lipid Profile

    Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
    Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
    Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
    Coronary Artery Disease II: Pathophysiology01:26

    Coronary Artery Disease II: Pathophysiology

    Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
    Coronary Artery Disease IV: Preventive Measures01:26

    Coronary Artery Disease IV: Preventive Measures

    Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
    Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

    Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

    Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
    Atherosclerosis III: Management01:26

    Atherosclerosis III: Management

    Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...